|
07-14-2026
|
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
|
|
07-03-2026
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
06-11-2026
|
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
|
|
06-05-2026
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
06-03-2026
|
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
|
|
06-02-2026
|
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
|
|
05-26-2026
|
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
|
|
05-19-2026
|
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
|
|
05-12-2026
|
Kura Oncology Reports First Quarter 2026 Financial Results
|
|
05-12-2026
|
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
|
